Estimating national trends in inpatient antibiotic use among US hospitals from 2006 to 2012

JAMA Internal Medicine

Volumn 176, Issue 11, 2016, Pages 1639-1648

  Baggs, James ^a   Fridkin, Scott K ^a   Pollack, Lori A ^a   Srinivasan, Arjun ^a   Jernigan, John A ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; GLYCOPEPTIDE; LINCOSAMIDE; MACROLIDE; METRONIDAZOLE; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFONAMIDE; TETRACYCLINE DERIVATIVE; ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CHILD; DRUG DATABASE; DRUG USE; EMERGENCY CARE; FEMALE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; INFANT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION SYSTEM; MIDDLE AGED; NEWBORN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREND STUDY; UNITED STATES; VERY ELDERLY; ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; COMPARATIVE STUDY; HOSPITAL; MEDICAID; MEDICARE; MULTICENTER STUDY; PRESCRIPTION; PRESCRIPTION DRUG MISUSE; PUBLIC HOSPITAL; STATISTICS AND NUMERICAL DATA; TRENDS;

ADULT; ANTI-BACTERIAL AGENTS; CHILD; DRUG PRESCRIPTIONS; DRUG RESISTANCE, MICROBIAL; HOSPITALS, PEDIATRIC; HOSPITALS, PUBLIC; HUMANS; INPATIENTS; LENGTH OF STAY; MEDICAID; MEDICARE; PATIENT DISCHARGE; PRESCRIPTION DRUG MISUSE; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84996522031     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2016.5651     Document Type: Article

References (39)

1. Fridkin SK, Srinivasan A. Implementing a strategy for monitoring inpatient antimicrobial use among hospitals in the United States. Clin Infect Dis. 2014; 58(3):401-406.
2. Fridkin S, Baggs J, Fagan R, et al; Centers for Disease Control and Prevention (CDC). Vital signs: improving antibiotic use among hospitalized patients. MMWR Morb Mortal Wkly Rep. 2014;63 (9):194-200.
3. Jacob JT, Gaynes RP. Emerging trends in antibiotic use in US hospitals: quality, quantification and stewardship. Expert Rev Anti Infect Ther. 2010; 8(8):893-902.
4. Centers for Disease Control and Prevention, US Department of Health and Human Services. Antibiotic resistance threats in the United States, 2013. http://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf. Accessed August 11, 2016.
5. The White House. National Strategy for Combating Antibiotic-Resistant Bacteria. https://www.whitehouse.gov/sites/default/files/docs/carb-national-strategy.pdf. Accessed August 11, 2016.
6. Pollack LA, Srinivasan A. Core elements of hospital antibiotic stewardship programs from the Centers for Disease Control and Prevention. Clin Infect Dis. 2014;59(suppl 3):S97-S100.
7. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 to June 2002, issued August 2002. Am J Infect Control. 2002;30(8): 458-475.
8. Fridkin SK, Steward CD, Edwards JR, et al. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis. 1999;29(2):245-252.
9. Magill SS, Edwards JR, Beldavs ZG, et al; Emerging Infections Program Healthcare-Associated Infections and Antimicrobial Use Prevalence Survey Team. Prevalence of antimicrobial use in US acute care hospitals, May-September 2011. JAMA. 2014; 312(14): 1438-1446.
10. Polk RE, Fox C, Mahoney A, Letcavage J, MacDougall C. Measurement of adult antibacterial drug use in 130 US hospitals: comparison of defined daily dose and days of therapy. Clin Infect Dis. 2007;44(5):664-670.
11. Pakyz AL, MacDougall C, Oinonen M, Polk RE. Trends in antibacterial use in US academic health centers: 2002 to 2006. Arch Intern Med. 2008;168 (20):2254-2260.
12. MacDougall C, Polk RE. Variability in rates of use of antibacterials among 130 US hospitals and risk-adjustment models for interhospital comparison. Infect Control Hosp Epidemiol. 2008; 29(3):203-211.
13. Pakyz AL, Gurgle HE, Ibrahim OM, Oinonen MJ, Polk RE. Trends in antibacterial use in hospitalized pediatric patients in United States academic health centers. Infect Control Hosp Epidemiol. 2009;30 (6):600-603.
14. Lasky T, Ernst FR, Greenspan J,Wang S, Gonzalez L. Estimating pediatric inpatient medication use in the United States. Pharmacoepidemiol Drug Saf. 2011;20(1):76-82.
15. Polk RE, Hohmann SF, Medvedev S, Ibrahim O. Benchmarking risk-adjusted adult antibacterial drug use in 70 US academic medical center hospitals. Clin Infect Dis. 2011;53(11):1100-1110.
16. Pakyz AL, Carroll NV, Harpe SE, Oinonen M, Polk RE. Increase in use of vancomycin for Clostridium difficile infection in US hospitals. Infect Control Hosp Epidemiol. 2010;31(8):867-868.
17. US Food and Drug Administration. National Drug Code Directory. http://www.fda.gov/Drugs/informationondrugs/ucm142438.htm. Accessed June 9, 2014.
18. WHO Collaborating Centre for Drug Statistics Methodology. International Language for Drug Utilization Research ATC/DDD. http://www.whocc .no/. Accessed June 9, 2014.
19. Centers for Medicare & Medicaid Services. Cost Reports. http://www.cms.gov/Research-Statistics-Data-and-Systems/Files-for-Order/costreports/index.html. Accessed June 9, 2014.
20. Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7): 749-759.
21. World Health Organization. International Classification of Diseases, Ninth Revision (ICD-9). Geneva, Switzerland:World Health Organization; 1977.
22. Baggs J, Fridkin S, Pollack LA, Srinivasan A, Jernigan J. Factors Associated with Inter-Hospital Variability of Inpatient Antibiotic Use in a Cohort of US Hospitals. Previous presentation: idweek; October 7-11, 2015; San Diego, CA.
23. Lessa FC,Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372(9):825-834.
24. Sievert DM, Ricks P, Edwards JR, et al; National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol. 2013;34 (1):1-14.
25. CDC's Antibiotic Resistance Patient Safety Atlas http://www.cdc.gov/hai/surveillance/ar-patient-safety-atlas.html. Accessed June 20, 2016, 2016.
26. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis. 2014;59(2):147-159.
27. Cooke J, Stephens P, Ashiru-Oredope D, et al. Longitudinal trends and cross-sectional analysis of English national hospital antibacterial use over 5 years (2008-13): working towards hospital prescribing quality measures. J Antimicrob Chemother. 2015;70(1):279-285.
28. Dumartin C, L'Hériteau F, PéfauM, et al. Antibiotic use in 530 French hospitals: results from a surveillance network at hospital and ward levels in 2007. J Antimicrob Chemother. 2010;65(9): 2028-2036.
29. European Centre for Disease Prevention and Control (ECDC). Antimicrobial resistance interactive database (EARS-Net) http://ecdc.europa.eu/en/healthtopics/antimicrobial-resistance/database/Pages/database.aspx. Accessed June 20, 2016, 2016.
30. Ashiru-Oredope D, Sharland M, Charani E, McNulty C, Cooke J; ARHAI Antimicrobial Stewardship Group. Improving the quality of antibiotic prescribing in the NHS by developing a new Antimicrobial Stewardship Programme: Start Smart-Then Focus. J Antimicrob Chemother. 2012; 67(suppl 1):i51-i63.
31. Wilcox MH, Shetty N, Fawley WN, et al. Changing epidemiology of Clostridium difficile infection following the introduction of a national ribotyping-based surveillance scheme in England. Clin Infect Dis. 2012;55(8):1056-1063.
32. Dellit TH, Owens RC, McGowan JE Jr, et al; Infectious Diseases Society of America; Society for Healthcare Epidemiology of America. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44 (2):159-177.
33. Mandell LA,Wunderink RG, Anzueto A, et al; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(suppl 2):S27-S72.
34. Baggs J, Gee J, Lewis E, et al. The Vaccine Safety Datalink: A model for monitoring immunization safety. Pediatrics. 2011;127(suppl 1): S45-S53.
35. Lieu TA, Hinrichsen VL, Moreira A, Platt R. Collaborations in population-based health research: The 17th annual HMO Research Network Conference, March 23-25, 2011, Boston, Massachusetts, USA. Clin Med Res. 2011;9(3-4): 137-140.
36. Platt R, Davis R, Finkelstein J, et al. Multicenter epidemiologic and health services research on therapeutics in the HMO Research Network Center for Education and Research on Therapeutics. Pharmacoepidemiol Drug Saf. 2001;10(5): 373-377.
37. Platt R, Carnahan RM, Brown JS, et al. The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction. Pharmacoepidemiol Drug Saf. 2012;21(suppl 1):1-8.
38. Fleurence RL, Curtis LH, Califf RM, Platt R, Selby JV, Brown JS. Launching PCORnet, a national patient-centered clinical research network. J Am Med Inform Assoc. 2014;21(4):578-582.
39. Beus JM, Ross R, Metjian TA, Gerber JS. The Performance of Administrative Data for Measurement of Antibiotic Use Varies Across Antibiotics. Previous presentation: idweek; October 7-11, 2015; San Diego, CA.